A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Latest Information Update: 16 Apr 2024
At a glance
- Drugs BMS-986442 (Primary) ; Programmed cell death-1 receptor antagonists
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 25 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2023 Planned End Date changed from 1 Sep 2025 to 30 Sep 2025.
- 13 Jan 2023 Planned primary completion date changed from 1 Sep 2023 to 30 Sep 2023.